Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies
American Association for Cancer Research
FDA Veteran Paz Vellanki, MD, joins Precision to become one of 3 ex-FDA oncology leaders supporting clients